Martha Goldberg Aronson - Apr 27, 2023 Form 4 Insider Report for Cardiovascular Systems Inc (CSII)

Role: Director
Signature: /s/ Andrew Nick as Attorney-in-Fact for Martha Goldberg Aronson pursuant to Power of Attorney previously filed.
Stock symbol: CSII
Transactions as of: Apr 27, 2023
Transactions value $: -$248,220
Form type: 4
Date filed: 4/27/2023, 04:35 PM
Previous filing: Aug 17, 2022
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	CSII	Common Stock	Disposed to Issuer	-$248K	-12.4K	-100%	$20.00	0	Apr 27, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CSII	Restricted Stock Units	Disposed to Issuer	$0	-29.8K	-100%	$0.00	0	Apr 27, 2023	Common Stock	29.8K		Direct	F2

Martha Goldberg Aronson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.
F2	Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.

Content

Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.

Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.